FY26 takeda OCT-NOV
Ended Awarded Last action
- Contract number
- 15B50926F00000018
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624
- Awarding agency
-
Federal Correctional Institution Fort Worth
Correctional Facilities, Department of Justice
- Obligated
- $319,552
Award facts
- Contract value 100% obligated
- $319,551.93 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lexington, MA 02421, USA
Award details come from SAM.gov/FPDS.
About this award
Takeda Pharmaceuticals America Inc. received a $319,551.93 firm fixed-price delivery order from the Federal Correctional Institution Fort Worth on October 1, 2025, with performance completion targeted for September 30, 2026. This delivery order, issued under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB), represents a child contract leveraging pre-negotiated terms and pricing established through Takeda's broader federal contracting vehicles. The award carries no set-aside designation, reflecting the specialized and often single-source nature of the pharmaceutical products being procured. Performance will occur in Lexington, Massachusetts, where Takeda maintains its headquarters as a subsidiary of Japan-based Takeda Pharmaceutical Company Limited.
This delivery order supports the Bureau of Prisons' pharmaceutical supply requirements by drawing from Takeda's extensive portfolio of advanced medications addressing rare diseases, hematology, immunology, oncology, and critical medical conditions. The company maintains an established federal contracting presence across multiple agencies, including the Department of Veterans Affairs and the Department of Justice, with a substantial single-award Blanket Purchase Agreement valued at $131.04 million for the period July 15, 2025 through July 14, 2026. The specialized nature of Takeda's product offerings—including treatments for hereditary angioedema, hemophilia, immune disorders, and rare metabolic conditions—underscores the critical role these pharmaceuticals play in federal healthcare delivery across correctional and medical facilities.
Quick answers
Who was awarded contract 15B50926F00000018?
15B50926F00000018 was awarded to Takeda Pharmaceuticals America, Inc. by Federal Correctional Institution Fort Worth (Correctional Facilities) on October 1, 2025.
How much is contract 15B50926F00000018 worth?
The government has obligated $319,552 on 15B50926F00000018.
Is contract 15B50926F00000018 an order under another contract?
Yes. 15B50926F00000018 is a delivery order under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 15B50926F00000018 competed?
The extent of competition for 15B50926F00000018 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award